A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer
- PMID: 12499095
- DOI: 10.1016/s0169-5002(02)00308-2
A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer
Abstract
With the availability of chemotherapy agents for first- and second-line treatment of advanced non-small-cell lung cancer (NSCLC), the patient population that requires subsequent chemotherapy is increasing. This retrospective analysis was performed to describe the clinical course after two standard or approved chemotherapy agents in patients with good overall performance status. Data were selected from patients with advanced NSCLC who had received third- or fourth-line chemotherapy after two prior chemotherapy regimens that included platinum and docetaxel given concurrently or sequentially. Prior regiments had failed due to discase progression within 90 days of chemotherapy, or unacceptable toxicity. Examination of over 700 patient records between January 1993 and January 2000 at one US and one European cancer centre revealed 43 patients that fulfilled the inclusion criteria. Response rates decreased with each line of treatment: first line, 20.9%; second line, 16.3%; third line, 2.3%; and fourth line, 0%. The disease control rate (response plus stable disease) also decreased dramatically from first- to fourth-line treatment, although it was higher for second-line treatment (74.4%) than for first-line treatment (62.8%). The median overall survival time from diagnosis was 16.4 months. The median overall survival time from the start of the last treatment (either third or fourth line) was 4 months. Patients with stage III disease at diagnosis had a longer overall survival from diagnosis than patients with stage IV disease (P=0.02). This review highlights the need for novel therapy approaches for patients with recurrent NSCLC who have failed second-line therapy and provides a baseline for the statistical design of such studies.
Similar articles
-
Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer.Clin Lung Cancer. 2012 Jan;13(1):39-43. doi: 10.1016/j.cllc.2011.06.008. Epub 2011 Sep 3. Clin Lung Cancer. 2012. PMID: 21890422
-
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.J Clin Oncol. 2000 Jun;18(12):2354-62. doi: 10.1200/JCO.2000.18.12.2354. J Clin Oncol. 2000. PMID: 10856094 Clinical Trial.
-
Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy.Lung Cancer. 2008 Aug;61(2):262-5. doi: 10.1016/j.lungcan.2008.02.002. Epub 2008 Mar 20. Lung Cancer. 2008. PMID: 18358559
-
Docetaxel for previously treated non-small-cell lung cancer.Oncology (Williston Park). 2002 Jun;16(6 Suppl 6):45-51. Oncology (Williston Park). 2002. PMID: 12108897 Review.
-
Docetaxel for locally advanced or metastatic non-small-cell lung cancer. Current data and future directions as front-line therapy.Oncology (Williston Park). 2002 Jun;16(6 Suppl 6):53-62. Oncology (Williston Park). 2002. PMID: 12108898 Review.
Cited by
-
Chemotherapy Use, Performance Status, and Quality of Life at the End of Life.JAMA Oncol. 2015 Sep;1(6):778-84. doi: 10.1001/jamaoncol.2015.2378. JAMA Oncol. 2015. PMID: 26203912 Free PMC article.
-
Episensitization: Defying Time's Arrow.Front Oncol. 2015 Jun 11;5:134. doi: 10.3389/fonc.2015.00134. eCollection 2015. Front Oncol. 2015. PMID: 26125013 Free PMC article. Review.
-
Association of Early Palliative Care With Chemotherapy Intensity in Patients With Advanced Stage Lung Cancer: A National Cohort Study.J Thorac Oncol. 2019 Feb;14(2):176-183. doi: 10.1016/j.jtho.2018.09.029. Epub 2018 Oct 15. J Thorac Oncol. 2019. PMID: 30336324 Free PMC article.
-
Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer.Curr Oncol Rep. 2005 Jul;7(4):241-7. doi: 10.1007/s11912-005-0045-6. Curr Oncol Rep. 2005. PMID: 15946581 Review.
-
Activity of topotecan given intravenously for 5 days every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: a phase II study.Invest New Drugs. 2011 Dec;29(6):1459-64. doi: 10.1007/s10637-010-9442-2. Epub 2010 May 13. Invest New Drugs. 2011. PMID: 20464446 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical